April 17, 2023/Cancer/Research

Breast Cancer Diagnosis at First Mammogram Much More Prevalent in Black Women

Study calls attention to the need for screenings at age 40 or younger

23-CNR-3682809-CQD-Hero-650×450 breast cancer article

Black women are significantly more likely to be diagnosed with breast cancer at the time of their first mammogram (47.6%) compared with White women (26%) and other groups (34.8%), according to a recent retrospective study undertaken by Cleveland Clinic’s Section of Breast Surgery within the Department of General Surgery. Women diagnosed on their first mammogram were more likely to be younger and have greater disease burden.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Inconsistencies in current screening recommendations – along with shortfalls of existing screening models – may be contributing factors in later disease presentation, and consequently, increased mortality among young Black women.


Initiating annual mammograms at age 40 has proven to be the single best way to reduce breast cancer-related deaths. Despite this, screening recommendations are not consistent across medical societies and other organizations. The American College of Radiology, Society of Breast Surgeons and American College of Obstetricians and Gynecologists all recommend starting annual mammograms at age 40. The American Cancer Society advises starting at age 45. And the U.S. Preventative Services Task Force – who many PCPs follow – has only recently updated the age of screening from 50 to 40 years.

Black women experience the highest rates of breast cancer earlier than age 50 and often present with more aggressive tumor biology. They are 42% more likely to die from the disease, so any delay in screening beyond age 40 is associated with increased risk. Although some inequities can be attributed to socioeconomic consequences of structural racism such as barriers to healthcare access and inequitable resource distribution (i.e., mammography screening and endocrine therapy), those factors alone do not explain the disparity in outcomes.

To help uncover ways to assess risk and individualize risk assessment and management, the research team sought to better understand just how much the inconsistencies in screening recommendations affect women who are diagnosed younger and with more aggressive disease. “We’re trying to understand more about cancer disparities and differentiate between factors that occur for socioeconomic reasons versus factors that can occur because there are differences in how the disease acts in different populations,” says Zahraa AlHilli, MD, MBA, study senior author and a general surgeon with Cleveland Clinic’s Digestive Disease and Surgery Institute. “Understanding these differences will help us better stratify risk.”

Study design

This retrospective cohort study included 738 women ages 40-45 who received treatment for breast cancer at Cleveland Clinic between 2010-2019. “We looked specifically at women between the ages of 40-45 because that is the age group that faces the most discordance in screening recommendations,” says Avia Wilkerson, MD, PhD, lead author of the study and a general surgery resident at Cleveland Clinic


Using the Cleveland Clinic tumor registry and electronic health record system, the researchers analyzed demographic, clinical and radiologic data for each patient. Having access to this registry enabled the researchers to understand not just the raw data but also obtain details about each patient’s diagnosis and treatment.

Study findings

The researchers’ hypothesis was that differences in screening recommendations was a contributing factor to why young Black women were presenting with later stage disease. The study data supported their hypothesis to a striking degree. Nearly half of Black women in the study were diagnosed at first mammogram – significantly more than any other racial group. Women diagnosed at their first mammogram were more likely to be diagnosed at an advanced clinical stage, and with metastatic disease.

The median age at first mammogram was 42.8 years for patients diagnosed on their first mammogram. Compared with the overall cohort of young women with breast cancer, the patients diagnosed on their first mammogram were younger and more often lacked a family history of disease. A statistically significant number of these patients had other risk factors such as high body mass indices, smoking and/or breast cancer symptoms at presentation.

These findings reinforce the fact that Black women would benefit from starting mammograms at age 40, and for those with an elevated lifetime risk, even sooner. “As a patient approaches age 40, it’s important to have a discussion about breast screening awareness, and whether they have risk factors,” says Dr. AlHilli.

Notably, current breast cancer risk assessment models were produced using data predominantly from patients of European descent. “These models don’t work well for predicting risk in women of other races,” explains Dr. Wilkerson. “In some Hispanic women it often overestimates risk while in Black women it can underestimate risk.”


Next steps

Although new models are needed to more accurately assess each patient’s individual risk, it is clear that in lieu of these, commencing screenings at age 40 is prudent, with some women at higher risk requiring an earlier start.

In the meantime, the researchers have presented further work studying the impact of first mammogram-detected cancer on breast cancer recurrence and survival at the American College of Surgeons Clinical Congress. Dr. Wilkerson is also conducting translational research into the biology of breast cancer tumors and their role in breast cancer disparities.

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 1, 2024/Cancer/Research
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024/Cancer/Research
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy